Eutilex Company

Eutilex is a develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products.
Technology:
CAR-T therapy, Regenerative Medicine
Industry:
Biopharma, Biotechnology, Medical, Private
Headquarters:
Seoul, Seoul-t'ukpyolsi, South Korea
Founded Date:
2015-01-01
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
4
Total Funding:
18072626
Estimated Revenue:
Less than $1M
Last Funding Date:
2016-12-08
Last Funding Type:
Series A
Register and Claim Ownership